An embodiment of the present invention is to provide a bioabsorbable medical material having adhesiveness to a biological tissue and improved degradability. A bioabsorbable medical material according to an embodiment of the present invention contains a crosslinked polymer material forming a specific shape, and a disintegration delaying material retained by the crosslinked polymer material. The crosslinked polymer material has degradability in water, the degradability being suppressed in the presence of an acid. The disintegration delaying material releases 0.5 mol%/day or greater of an acid until the seventh day upon contact with water at 37° C.

[Problem] An adhesion-preventing material having a high adhesion-preventing effect has been demanded. [Solution] An adhesion-preventing material including a sterilized biocompatible sponge-like laminate, wherein the sponge-like laminate comprises a sponge-like first layer and a sponge-like second layer each of which is at least partially crosslinked with a curing agent and comprises a low-endotoxin alginic acid monovalent metal salt, the alginic acid monovalent metal salt in the first layer has a weight average molecular weight of 10,000 to 2,000,000, the alginic acid monovalent metal salt in the second layer has a weight average molecular weight of 1,000 to 1,000,000, the weight average molecular weights are measured by a GPC-MALS method after a decrosslinking treatment, and the weight average molecular weight of the alginic acid monovalent metal salt in the first layer is higher than that in the second layer.

[Problem] An adhesion-preventing material having a high adhesion-preventing effect has been demanded. [Solution] An adhesion-preventing material including a sterilized biocompatible sponge-like laminate, wherein the sponge-like laminate comprises a sponge-like first layer and a sponge-like second layer each of which is at least partially crosslinked with a curing agent and comprises a low-endotoxin alginic acid monovalent metal salt, the alginic acid monovalent metal salt in the first layer has a weight average molecular weight of 10,000 to 2,000,000, the alginic acid monovalent metal salt in the second layer has a weight average molecular weight of 1,000 to 1,000,000, the weight average molecular weights are measured by a GPC-MALS method after a decrosslinking treatment, and the weight average molecular weight of the alginic acid monovalent metal salt in the first layer is higher than that in the second layer.

A drug-releasing polymer composition is disclosed. It may include a major component, which may be ethylene vinyl acetate, and may further include at least one or two release-modifying materials, and may further include at least one or two drugs. The release-modifying materials may be polyethylene glycol and polycaprolactone. The drugs may be minocycline and rifampin. There may be an interaction such that in the presence of two different release-modifying materials, drug release may be greater than with either release-modifying material alone. There may be an interaction such that in the presence of two drugs, drug release may be greater than with either drug alone, and antibacterial performance may be enhanced. Release durations as long as two months are possible. In addition, the composition can be provided on a medical device that is configured for implanting in body tissue for an extended time period.

A drug-releasing polymer composition is disclosed. It may include a major component, which may be ethylene vinyl acetate, and may further include at least one or two release-modifying materials, and may further include at least one or two drugs. The release-modifying materials may be polyethylene glycol and polycaprolactone. The drugs may be minocycline and rifampin. There may be an interaction such that in the presence of two different release-modifying materials, drug release may be greater than with either release-modifying material alone. There may be an interaction such that in the presence of two drugs, drug release may be greater than with either drug alone, and antibacterial performance may be enhanced. Release durations as long as two months are possible. In addition, the composition can be provided on a medical device that is configured for implanting in body tissue for an extended time period.

The present invention relates to a drug-eluting nanoengineered medical implant/contact device. The device comprises a nanocomposite and a drug, wherein the nanocomposite comprises hydrophilic polymer domains, hydrophobic polymer domains, water pores, and boundary charged double layers; wherein when the drug is hydrophilic, at least 80% of the drug partitions in the boundary charged double layers formed at the boundary interface of the hydrophilic polymer domains and water pores, and when the drug is hydrophobic, at least 80% of the dmg partitions in the boundary charged double layers formed at the boundary interface of the hydrophobic polymer domains and water pores. The device is configured to sustain the release of the drug at high precision and long duration.

Described are transdermal drug delivery compositions comprising amphetamine, methods of making transdermal drug delivery compositions comprising amphetamine, and therapeutic methods of using them. In specific embodiments, the compositions are free of components with moieties that are reactive with amphetamine. In specific embodiments, the compositions are manufactured using solvents free of components with moieties that are reactive with amphetamine. Therapeutic methods using the compositions also are described.

The present invention concerns a bio-resorbable prosthesis (1, 1′) for organs with lumens, as blood vessels and the like, comprising at least one bio-absorbable material layer (2), intended to be arranged in contact with said lumen organ when said prosthesis (1, 1′) is implanted, and at least one auxetic material layer (3), arranged in contact with said at least one bio-absorbable material layer (2).

The present invention also concerns a method for the production of a bio-absorbable prosthesis (1, 1′).

The present invention concerns a bio-resorbable prosthesis (1, 1′) for organs with lumens, as blood vessels and the like, comprising at least one bio-absorbable material layer (2), intended to be arranged in contact with said lumen organ when said prosthesis (1, 1′) is implanted, and at least one auxetic material layer (3), arranged in contact with said at least one bio-absorbable material layer (2).

The present invention also concerns a method for the production of a bio-absorbable prosthesis (1, 1′).

A longitudinal extending body with oriented fibers comprised of an organic compound, preferably cellulose fibers, with a hydrophilic and hydrophobic polymer having absorbable and non res sorbable qualities in the body, with an internal construction to promote cell growth. The longitudinal body has at least one wall having oriented fiber to include cellulose fiber extending the length of said body. This extending body has a surface that is smooth to the touch for additional processing methods such as machining, compression molding and 3 D printing.